Pharmacological Combination Therapy for Parkinson's Disease
Managing Parkinson's disease often requires moving beyond a single pharmacological agent. This protocol addresses the structured combination approach — covering which agents are combined, under what conditions, and what the regimen targets.
Treatment Approach
The regimen is built around levodopa preparations used together with one or more additional pharmacological agent classes. The precise combination, sequencing, and the clinical circumstances that guide agent selection are set out in full in the protocol — only a partial overview is available here.
References
DOI: 10.1186/s42466-024-00325-4
- Pharmacological combination therapy should be considered following initial monotherapy when the efficacy of the initial monotherapy at an intermediate maintenance dose for dopa-sensitive target symptoms is inadequate or when the monotherapy's required dosage for symptom control cannot be achieved due to therapy-limiting side effects.
- Various combinations of Levodopa-preparations with dopamine-agonists and/or MAO-B inhibitors may be considered for combination therapy of PD without fluctuations.
View source ↗